Pregnant Women Serve as Primary Roll Out for COVID-19 Vaccination

High vulnerability of pregnant women to develop severe SARS-CoV-2 infection – COVID-19 schedules the need to consider them for COVID-19 vaccination.

High vulnerability of pregnant women to develop severe SARS-CoV-2 infection – COVID-19 and the unknown potency of the anti-SARS-CoV-2 immune response in their offsprings, schedules the need to consider them for COVID-19 vaccination, as per a study at Massachusetts General Hospital (MGH), published in JAMA Network Open.

127 pregnant women in their third trimester who received care at three Boston hospitals between April 2 and June 13, 2020, were included in the study. There were 64 women who tested positive for SARS-CoV-2, among which no virus in maternal or cord blood or placentas (despite detection in the women's respiratory system), were detected.

Potent Monoclonal Antibody for COVID 19 Unraveled
Ab1, a human monoclonal antibody that effectively neutralizes SARS-CoV-2, the virus that causes COVID-19 has been identified.

‘High vulnerability of pregnant women to develop severe SARS-CoV-2 infection – COVID-19 and the minimal potency of the anti-SARS-CoV-2 immune response in their offsprings, schedules the need to consider them for COVID-19 vaccination.’

COVID-19 antibodies

The team found no evidence of viral transmission to newborns, attributing the reason being lack of virus in the mothers' blood, as well as, absence of the virus gateway – ACE2 receptor and TMPRSS2 enzyme in the placenta.

Most of the women who tested positive developed antibody responses against SARS-CoV-2 proteins, but mother-to-newborn transfer of anti-SARS-CoV-2 antibodies through the placenta was significantly lower than transfer of anti-influenza antibodies.

COVID-19 : How the Risk Factors Contribute to Treatment Options
COVID-19 has greater potency to affect hospitalized patients who are obese, have complications from diabetes or hypertension, especially in men.

"Our finding of compromised mother-to-baby transfer of SARS-CoV-2-specific antibodies in third trimester infections has implications for maternal vaccine administration. Specifically, it highlights that pregnant women are a key population to consider in vaccine rollouts. It also raises questions regarding the optimal timing of vaccine administration to best support maternal and newborn immunity," says lead author Andrea Edlow, MD, a maternal-fetal medicine specialist at MGH and an assistant professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School.

The study thus highlights the mechanisms that underlie for the ineffectual transfer of SARS-CoV-2-specific antibodies after third trimester infection. This would help understand further actions of vaccine-generated antibodies.

Source-Medindia

New Drug Against COVID-19 Discovered
New drug compounds that target the protein complex – SKI complex, responsible for the replication and survival of coronaviruses, have been discovered.